Asia Pacific Predictive Disease Analytics Market To Reach $2448.46 Million By 2030

Asia Pacific Predictive Disease Analytics Market Growth & Trends

The Asia Pacific predictive disease analytics market size is expected to reach USD 2448.46 million by 2030, registering a CAGR of 24.0% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising pressure of increasing healthcare costs and reduced patient engagement and retention. Moreover, rising investment for technological development in this space by prominent players is driving the market growth. Furthermore, major players, such as IBM Corp., Verisk Analytics, Inc., McKesson Corp., SAS Institute, Inc., Cotiviti, Inc., Optum, Inc., MedeAnalytics, Inc., and Oracle Corp., are undertaking various strategies, such as partnerships, acquisitions, collaborations, product launches, and expansions.

For instance, in April 2022, SAS Institute, Inc. and Microsoft collaborated to build deep technology integrations to make advanced healthcare analytics accessible. This collaboration would enable the use of Fast Healthcare Interoperability Resources by integrating Azure Health Data Services into SAS Health. In December 2020, McKesson Corp. launched an oncology technology and insights business, Ontada. This helped the company advance cancer research and care. Moreover, government support in the form of funding and initiatives will drive the market over the forecast period. According to a study conducted by the Asian Development Bank in August 2022, the adoption of remote patient monitoring and predictive analytics can contribute an estimated USD 9.4 billion and USD 15.5 billion, respectively to the gross domestic product across Southeast Asia by 2030.

 Request a free sample copy or view report summary: Asia Pacific Predictive Disease Analytics Market Report

Asia Pacific Predictive Disease Analytics Market Report Highlights

• The software & services segment accounted for the largest share of 70.8% in 2022 and is anticipated to register the fastest CAGR of 24.4% over the forecast period. The growing patient load on healthcare facilities and the rising prevalence of diseases are encouraging healthcare systems to adopt predictive analytics tools

• The on-premise deployment segment dominated the market in 2022 with a revenue share of 65.2% owing to the benefits associated with the adoption of on-premise solutions, such as reduced costs, low power consumption, and low maintenance

• The healthcare payersend-use segment dominated the market with a share of 40.8% in 2022 owing to the high adoption of predictive disease analytics tools to evaluate claims for insurance

• India dominated the overall market in 2022 with a share of 23.6% owing to the presence of developing healthcare infrastructure and favorable government policies

Asia Pacific Predictive Disease Analytics Market Segmentation

Grand View Research has segmented the Asia Pacific predictive disease analytics market based on component, deployment, end-use, and country:

Asia Pacific Predictive Disease Analytics Component Outlook (Revenue, USD Million, 2018 - 2030)

• Hardware

• Software & Services

Asia Pacific Predictive Disease Analytics Deployment Outlook (Revenue, USD Million, 2018 - 2030)

• On-premise

• Cloud-based

Asia Pacific Predictive Disease Analytics End-Use Outlook (Revenue, USD Million, 2018 - 2030)

• Healthcare Payers

• Healthcare Providers

• Other End-users

Asia Pacific Predictive Disease Analytics Country Outlook (Revenue, USD Million, 2018 - 2030)

• China

• Japan

• India

• Australia

• Singapore

• Malaysia

• Indonesia

• Vietnam

List of Key Players in the Asia Pacific Predictive Disease Analytics Market

• IBM Corp.

• Verisk Analytics, Inc.

• McKesson Corp.

• SAS Institute, Inc.

• Cotiviti, Inc.

• Optum, Inc.

• MedeAnalytics, Inc.

• Oracle